BioSpace News Archive

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced the appointment of Curt Bradshaw, Ph.D., as its new Chief Scientific Officer.

Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, today announced the acquisition of rights to Hemera Biosciences, LLC’s investigational gene therapy HMR59, administered as a one-time, outpatient, intravitreal injection to help preserve vision in patients with geographic atrophy, a late-stage and severe form of age-related macular degeneration (AMD)

AbbVie (NYSE: ABBV), today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein targets.

Elusys Therapeutics, Inc. announced that the European Commission has approved obiltoxaximab, the company’s monoclonal antibody anthrax antitoxin for the treatment of inhalation anthrax.

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that the first patient has been dosed in the Phase 3 ASPEN study of brensocatib in patients with bronchiectasis.

Sutter Health, a not-for-profit healthcare system, and Aetna, a CVS Health Company, announced Jeb Dunkelberger as the new Chief Executive Officer of the Sutter Health | Aetna joint venture, which offers both self-insured PPO and EPO commercial health plan products, as well as Aetna offered fully-insured products to employers in Northern California.

AbbVie (NYSE: ABBV), today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein targets.

Pear Therapeutics, Inc. today announced that Corey McCann, M.D., Ph.D., President and CEO, will participate in a fireside chat at the 2020 RBC Capital Markets Healthcare Private Company Conference on Wednesday, December 16 at 10:00 a.m. Eastern Time.

The rising disposable income of people around the world is promoting a shift from conventional to advanced wound care products, which in turn is providing a significant push to the global medical foam market.

Keratosis Pilaris is a non-contagious skin disorder that causes the outermost layers of skin to thicken, especially on the upper arms and thighs, buttocks, and on the face